PRESS RELEASE: EU based Bio Pharm Company MGC Pharmaceuticals signs distribution agreement with Health House International.
MGC Pharmaceuticals (ASX: MXC) have signed a distribution agreement with highly regarded specialist medical cannabis company Health House International, and it’s set to benefit patients in Australia.
Health House International was granted the first medicinal cannabis import licence in Australia and will provide MGC Pharmaceuticals access through its wide supply network of affiliated pharmacies in all states of Australia, along with its network of prescribing doctors, hospital and associated clinical research facilities.
Health House founder and CEO Paul Mavor who is overseeing the expansion of Health House into the UK market in the following months and is a registered pharmacist both in the UK and Australia said he was excited to be distributing MGC products.
“They represent cutting edge technology in this industry that is backed up by ongoing research”.
“MGC has a great selection of products with different formulations targeting different medical conditions that prescribers will have confidence in.” Mr Mavor said.
“Our distribution and supply chain network is unique with Health House employing specialist cannabinoid pharmacists trained in all aspects of the supply process such as compliance, regulatory advice, approvals process, dosage, and drug interactions. We make it easy for Doctors to prescribe and pharmacists to dispense ensuring product reaches patients in a timely and safe manner” Mr Mavor said deliveries are overnight to all capital cities in Australia.
Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals says: “These agreements endorse our phytocannabinoid based product range, significantly expand our distribution in Australia and demonstrate that we are at the forefront of our industry,”
MGC has already received purchase orders under the agreements, which cover its proprietary cannabinoid treatments, including CannEpil for the treatment of Epilepsy and CogniCann for the treatment of Dementia and Alzheimer’s.
The agreements further includes two additional MGC formulations: MXP100, which is the company’s CBD only formulation, and MXC 1:1, a 50/50 mix of CBD/THC which was developed for the relief from symptoms of spasticity and certain types of inflammatory pain with all four applications permitted by the Australian Therapeutic Goods Administration (TGA) for supply in either clinical trials or under the special access scheme.
The deal has also been left open to include any additional MGC formulations that may be developed for commercial use.
Health House International Pty Ltd
www.healthhouse.com.au
[email protected]
08 9444 2444